SARS-CoV 2 imaging study award to the UK Biobank

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:5 publications

Grant number: MC_PC_21051

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2022
  • Known Financial Commitments (USD)

    $4,763,304.27
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Mark Effingham
  • Research Location

    United Kingdom
  • Lead Research Institution

    UK Biobank
  • Research Priority Alignment

    N/A
  • Research Category

    14

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Medical Research Council (MRC) has agreed to provide a COVID-19 Support Fund award to UK Biobank to help underpin short-term stability and to avoid deterioration of strategic, national scientific capability as a result of impacts of the COVID-19 pandemic. Purpose By accepting this award, the organisation agrees to use the MRC COVID-19 Support Fund to help ensure MRC objectives continue to be met, the value of MRC investments continue to be realised, and to sustain the research skills and capability within their organisation that will be needed to underpin the post-pandemic national recovery. The award is specifically to maximise the number of participants within the core imaging programme.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.

SARS-CoV-2 is associated with changes in brain structure in UK Biobank.